ALEC Stock Analysis: Buy, Sell, or Hold?
ALEC - Alector, Inc. Common Stock
$2.36
0.10 (4.42%)
▲
5d:
+20.41%
30d:
+58.39%
90d:
+6.79%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When ALEC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: ALEC is 19.8% above its trading range ($1.97). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: ALEC is 19.8% above its trading range ($1.97). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: ALEC is currently trading at $2.36, which is considered extended relative to its 30-day fair value range of $1.41 to $1.97.
Technical Outlook: Technically, ALEC is in a strong uptrend. Immediate support is located at $1.60, while resistance sits at $2.52. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: ALEC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.10 (+31.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ALEC is in a strong uptrend. Immediate support is located at $1.60, while resistance sits at $2.52. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: ALEC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.10 (+31.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.41 -
$1.97
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+19.8% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.4%)
- BULLISH: Trading 31.4% below Wall St target ($3.10)
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.41 -
$1.97
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.60
Resistance Level
$2.53
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.16
Wall Street Target
$3.10
(+31.4%)
Revenue Growth (YoY)
-57.8%
Earnings Growth (YoY)
-86.3%
Share & Embed Analysis
Last updated: August 23, 2026 1:24 AM ET
Data refreshes hourly during market hours. Next update: 2:24 AM
Data refreshes hourly during market hours. Next update: 2:24 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALEC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Grace Wong-Sarad
SELL
1820 shares
2026-04-16
Grace Wong-Sarad
SELL
1000 shares
2026-03-10
Grace Wong-Sarad
SELL
4079 shares
2026-02-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1100 | 43 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 39 SELL |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 26 SELL |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
